The second Philadelphia Prostate Cancer Consensus Conference recommends the use of a comprehensive gene panel that should include BRCA1, BRCA2 and MMR genes (MSH2, MLH1, PMS2, MSH6 and EPCAM). This evidence concerns the gene MSH2 and Familial prostate cancer.